Alpha 2.0
Login Register
» Authors » Marketa Palacova

Marketa Palacova

Explore the profile of Marketa Palacova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 983
Followers 0
Related Specialties
Oncology
General Medicine
Pathology
Top 10 Co-Authors
Katarina Petrakova
Marek Svoboda
Rostislav Vyzula
Zdenek Kleibl
Marie Navratilova
Pavel Fabian
Mario Campone
Michelino De Laurentiis
Petra Vasickova
Lenka Foretova
Published In
Klin Onkol
Diagn Pathol
Breast Cancer Res Treat
Hered Cancer Clin Pract
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
Freyer G, Martinez-Janez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Munoz M, et al.
Breast . 2024 Feb; 74:103681. PMID: 38377732
Introduction: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic...
2.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
Borstnar S, Palacova M, Lacko A, Timcheva C, Nili Gal-Yam E, Papazisis K, et al.
Radiol Oncol . 2022 May; 56(2):238-247. PMID: 35575587
Background: The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a...
3.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, et al.
Breast Cancer Res Treat . 2022 Feb; 193(1):95-103. PMID: 35212906
Purpose: CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB + LET) in a large, diverse cohort who have...
4.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Dieras V, Han H, Kaufman B, Wildiers H, Friedlander M, Ayoub J, et al.
Lancet Oncol . 2020 Aug; 21(10):1269-1282. PMID: 32861273
Background: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we...
5.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Saura C, Oliveira M, Feng Y, Dai M, Chen S, Hurvitz S, et al.
J Clin Oncol . 2020 Jul; 38(27):3138-3149. PMID: 32678716
Purpose: NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI,...
6.
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno
Holanek M, Bilek O, Nenutil R, Kazda T, Selingerova I, Zvarikova M, et al.
Klin Onkol . 2019 Aug; 32(Supplementum2):31-35. PMID: 31409079
Background: Mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing breast cancer. Tumors arising from this mutation are expected to be more sensitive to...
7.
Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer
Palacova M
Klin Onkol . 2019 Aug; 32(Supplementum2):24-30. PMID: 31409078
Hereditary breast cancer syndrome is associated with a higher risk of developing breast cancer and accounts for 5-10% of all breast tumors. Is it possible that mutations in BRCA1/2 genes...
8.
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer
Foretova L, Navratilova M, Svoboda M, Vasickova P, Stahlova E, Hazova J, et al.
Klin Onkol . 2019 Aug; 32(Supplementum2):6-13. PMID: 31409076
An inherited predisposition to breast cancer underlies 5-10% of breast tumors. High-risk BRCA1 and BRCA2 genes result in an 85% lifetime risk of breast cancer and a 20-60% lifetime risk...
9.
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al.
Diagn Pathol . 2012 Mar; 7:31. PMID: 22439831
Background: Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast...
10.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.
Lancet . 2012 Jan; 379(9816):633-40. PMID: 22257673
Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that...